Molnupiravir: a novel efficacious antiviral candidate to COVID-19
DOI:
https://doi.org/10.33448/rsd-v10i15.23014Keywords:
COVID-19; Treatment; Nucleotide analog; Molnupiravir.Abstract
An unknown pneumonia-like disease has emerged in Wuhan, China, in late 2019. It is later named as SARS-CoV-2 which cause COVID-19. This virus spreads easily due to high mobilization and its transmission through droplets or aerosol and fomite. The World Health Organization (WHO) then declared this disease as a global outbreak in March 2020. As the world faces the outbreak of SARS-CoV-2, many researchers race to find the most efficacious treatment for COVID-19. Until now, the most common treatments for COVID-19 were only symptomatic such as decongestant, corticosteroid, interleukin inhibitor, and existing antiviral. The researchers then develop a brand new antiviral that works efficiently to inhibit SARS-CoV-2 and might become prophylaxis. This disease is called Molnupiravir or EIDD-2801, a nucleotide analog which inhibits SARS-CoV-2 replication, resulting in damaged mRNA and lethal virions. Molnupiravir works to produce mutagenesis in RNA viruses and prevent the virus from spreading widely throughout the human body. However, this drug is still needed to undergo clinical trial phase three. In this article, we will discuss how Molnupiravir works and its efficacy compared to existing drugs. This review article aims to provide an update about novel efficacious antiviral for COVID-19, Molnupiravir.
References
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., Ray, A. S., Cihlar, T., Siegel, D., Mackman, R. L., Clarke, M. O., Baric, R. S., & Denison, M. R. (2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio, 9(2). https://doi.org/10.1128/MBIO.00221-18
Consortium, W. S. T. (2021). Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. New England Journal of Medicine, 384(6), 497–511. https://doi.org/10.1056/nejmoa2023184
Fischer, W., Eron, J. J., Holman, W., Cohen, M. S., Fang, L., Szewczyk, L. J., Sheahan, T. P., Baric, R., Mollan, K. R., Wolfe, C. R., Duke, E. R., Azizad, M. M., Borroto-Esoda, K., Wohl, D. A., Loftis, A. J., Alabanza, P., Lipansky, F., & Painter, W. P. (2021). Molnupiravir, an Oral Antiviral Treatment for COVID-19. MedRxiv : The Preprint Server for Health Sciences. https://doi.org/10.1101/2021.06.17.21258639
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., Ge, J., Zheng, L., Zhang, Y., Wang, H., Zhu, Y., Zhu, C., Hu, T., Hua, T., Zhang, B., … Rao, Z. (n.d.). Structure of the RNA-dependent RNA polymerase from COVID-19 virus. http://science.sciencemag.org/
Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021). Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases, 102, 501–508. https://doi.org/10.1016/J.IJID.2020.10.069
Kabinger, F., Stiller, C., Schmitzová, J., Dienemann, C., Kokic, G., Hillen, H. S., Höbartner, C., & Cramer, P. (2021). Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature Structural & Molecular Biology. https://doi.org/10.1038/S41594-021-00651-0
Kaur, S. P., & Gupta, V. (2020). COVID-19 Vaccine: A comprehensive status report. https://doi.org/10.1016/j.virusres.2020.198114
Kirchdoerfer, R. N., & Ward, A. B. (2019). Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nature Communications 2019 10:1, 10(1), 1–9. https://doi.org/10.1038/s41467-019-10280-3
Majumder, J., & Minko, T. (2021). Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. The AAPS Journal, 23(14). https://doi.org/10.1208/s12248-020-00532-2
Painter, W. P., Holman, W., Bush, J. A., Almazedi, F., Malik, H., Eraut, N. C. J. E., Morin, M. J., Szewczyk, L. J., & Painter, G. R. (2021). Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2. https://doi.org/10.1128/AAC.02428-20
Petrosillo, N., Viceconte, G., Ergonul, O., Ippolito, G., & Petersen, E. (2020). COVID-19, SARS and MERS: are they closely related? In Clinical Microbiology and Infection (Vol. 26, Issue 6, pp. 729–734). Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2020.03.026
Robson, F., Shahed Khan, K., Le, T. K., Ment Paris, C., Demirbag, S., Barfuss, P., Rocchi, P., & Ng, W.-L. (2020). Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Molecular Cell, 79, 710–727. https://doi.org/10.1016/j.molcel.2020.07.027
Suteja, R., Novianti, P., Dewi, K., Widiyanti, E., Wijayanti, I., K, C., & Purnamasidhi, C. (2020). Migrant Workers of Indonesia: Transmission Channels of SARS-CoV-2 Amidst COVID-19 Pandemic in Indonesia. International Journal of Medical Reviews and Case Reports, 0, 1. https://doi.org/10.5455/ijmrcr.2020-05-197
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2020). Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews Microbiology 2020 19:3, 19(3), 155–170. https://doi.org/10.1038/s41579-020-00468-6
WHO. (2020). WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. WHO Director General’s Speeches, March, 4. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
Yousefifard, M., Zali, A., Ali, K. M., Neishaboori, A. M., Zarghi, A., Hosseini, M., & Safari, S. (2020). Antiviral therapy in management of COVID-19: a systematic review on current evidence. Archives of Academic Emergency Medicine, 8(1), 1–9. /pmc/articles/PMC7156260/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 I Wayan Sumardika; Cokorda Agung Wahyu Purnamasidhi; Agus Eka Darwinata; Giovanca Verentzia Purnama; Jerry Jerry; I Komang Hotra Adiputra; Richard Christian Suteja; I Gede Purna Weisnawa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
